HK1124329A1 - Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors - Google Patents
Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitorsInfo
- Publication number
- HK1124329A1 HK1124329A1 HK09103762.1A HK09103762A HK1124329A1 HK 1124329 A1 HK1124329 A1 HK 1124329A1 HK 09103762 A HK09103762 A HK 09103762A HK 1124329 A1 HK1124329 A1 HK 1124329A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- optionally substituted
- benzothiophenes
- indoles
- seo
- benzoselenophenes
- Prior art date
Links
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical class C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 title abstract 2
- 150000001907 coumarones Chemical class 0.000 title abstract 2
- 150000002475 indoles Chemical class 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 230000000986 microtubule polymerisation Effects 0.000 title abstract 2
- BNRDGHFESOHOBF-UHFFFAOYSA-N 1-benzoselenophene Chemical class C1=CC=C2[se]C=CC2=C1 BNRDGHFESOHOBF-UHFFFAOYSA-N 0.000 title 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 3
- 125000003107 substituted aryl group Chemical group 0.000 abstract 3
- 125000002252 acyl group Chemical group 0.000 abstract 2
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 125000005017 substituted alkenyl group Chemical group 0.000 abstract 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 2
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 abstract 1
- 125000004455 (C1-C3) alkylthio group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/80—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/83—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/86—Benzo [b] furans; Hydrogenated benzo [b] furans with an oxygen atom directly attached in position 7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D333/56—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
- C07F9/65517—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Optics & Photonics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Furan Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US76533706P | 2006-02-03 | 2006-02-03 | |
PCT/AU2007/000101 WO2007087684A1 (en) | 2006-02-03 | 2007-02-02 | Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1124329A1 true HK1124329A1 (en) | 2009-07-10 |
Family
ID=38327089
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK09103762.1A HK1124329A1 (en) | 2006-02-03 | 2009-04-23 | Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors |
Country Status (12)
Country | Link |
---|---|
US (5) | US8198466B2 (ja) |
EP (2) | EP1984333B1 (ja) |
JP (1) | JP5315060B2 (ja) |
AT (1) | ATE555091T1 (ja) |
AU (1) | AU2007211840B2 (ja) |
CA (1) | CA2640678C (ja) |
DK (1) | DK1984333T3 (ja) |
ES (1) | ES2386299T3 (ja) |
HK (1) | HK1124329A1 (ja) |
NZ (1) | NZ570014A (ja) |
PT (1) | PT1984333E (ja) |
WO (1) | WO2007087684A1 (ja) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0416206A (pt) | 2003-11-20 | 2006-12-26 | Janssen Pharmaceutica Nv | 2-quinolinonas e 2-quinoxalinonas substituìdas por 6-alquenila e 6-fenilalquila como inibidores de polimerase de poli(adp-ribose) |
JP4864717B2 (ja) | 2003-11-20 | 2012-02-01 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ポリ(adp−リボース)ポリメラーゼインヒビターとしての7−フェニルアルキル置換2−キノリノンおよび2−キノキサリノン |
AU2005259190B2 (en) | 2004-06-30 | 2011-05-12 | Janssen Pharmaceutica N.V. | Quinazolinedione derivatives as PARP inhibitors |
EA012416B1 (ru) | 2004-06-30 | 2009-10-30 | Янссен Фармацевтика Н.В. | Производные замещенного 2-алкилхиназолинона как ингибиторы parp |
ES2563954T3 (es) | 2004-06-30 | 2016-03-16 | Janssen Pharmaceutica Nv | Derivados de ftalazina como inhibidores de PARP |
WO2007087684A1 (en) | 2006-02-03 | 2007-08-09 | Bionomics Limited | Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors |
AU2008223793B2 (en) | 2007-03-08 | 2012-08-23 | Janssen Pharmaceutica Nv | Quinolinone derivatives as PARP and TANK inhibitors |
ES2448870T3 (es) | 2007-10-26 | 2014-03-17 | Janssen Pharmaceutica, N.V. | Derivados de quinolina como inhibidores de PARP |
RU2490260C2 (ru) | 2008-03-27 | 2013-08-20 | Янссен Фармацевтика Нв | Тетрагидрофенантридиноны и тетрагидроциклопентахинолиноны в качестве ингибиторов parp и ингибиторов полимеризации тубулина |
ATE513818T1 (de) | 2008-03-27 | 2011-07-15 | Janssen Pharmaceutica Nv | Chinazolinonderivate als tubulinpolymerisationshemmer |
US9006284B2 (en) * | 2009-08-27 | 2015-04-14 | Bionomics Limited | Combination therapy for treating proliferative diseases |
NZ598490A (en) * | 2009-08-27 | 2014-01-31 | Bionomics Ltd | Treatment of macular degeneration |
AU2009240878B2 (en) * | 2009-11-27 | 2016-05-26 | Bionomics Limited | Combination Therapy for Treating Proliferative Diseases |
WO2011063469A1 (en) * | 2009-11-27 | 2011-06-03 | Bionomics Limited | Tubulin biomarker assay |
US20110130367A1 (en) * | 2009-11-27 | 2011-06-02 | Bionomics Limited | Combination Therapy for Treating Proliferative Diseases |
US20130131018A1 (en) | 2010-06-04 | 2013-05-23 | Exonhit S.A. | Substituted isoquinolines and their use as tubulin polymerization inhibitors |
WO2012006686A1 (en) | 2010-07-16 | 2012-01-19 | Bionomics Limited | Chemical processes for the manufacture of substituted benzofurans |
FR2962731B1 (fr) * | 2010-07-19 | 2012-08-17 | Sanofi Aventis | Procede de preparation de derives d'amino-benzoyl-benzofurane |
WO2012048058A2 (en) * | 2010-10-06 | 2012-04-12 | J-Pharma Co., Ltd. | Developing potent urate transporter inhibitors: compounds designed for their uricosuric action |
US9090633B2 (en) | 2010-11-18 | 2015-07-28 | Kasina Laila Innova Pharmaceuticals Private Limited | Substituted 4-(arylamino) selenophenopyrimidine compounds and methods of use thereof |
AU2011330730B2 (en) | 2010-11-18 | 2016-02-18 | Kasina Laila Innova Pharmaceuticals Private Limited | Substituted 4-(selenophen-2(or 3)-ylamino)pyrimidine compounds and methods of use thereof |
WO2012077135A2 (en) * | 2010-12-09 | 2012-06-14 | Kasina Laila Innova Pharmaceuticals Private Limited | Substituted 4-(arylamino) selenophenopyrimidine compounds and methods of use thereof |
US9039732B2 (en) | 2011-07-11 | 2015-05-26 | Covidien Lp | Surgical forceps |
CN103906742A (zh) * | 2011-09-28 | 2014-07-02 | 世宗大学校产学协力团 | 硒吩稠合芳族化合物和其制备方法 |
AU2013204313C1 (en) * | 2012-06-01 | 2016-04-07 | Bionomics Limited | Combination Therapy |
CN103058988B (zh) * | 2012-12-31 | 2015-09-02 | 中国人民大学 | 苯并噻吩及其衍生物及其制备方法与应用 |
WO2014175623A1 (ko) * | 2013-04-26 | 2014-10-30 | 한국생명공학연구원 | 신규 튜불린 중합 저해제 및 그 합성방법 |
KR101584731B1 (ko) | 2013-04-26 | 2016-01-12 | 한국생명공학연구원 | 신규 튜불린 중합 저해제 및 그 합성방법 |
CA2944517C (en) * | 2014-04-04 | 2021-03-09 | Bionomics Limited | Method for treating chronic lymphocytic leukemia |
WO2015179893A1 (en) * | 2014-05-30 | 2015-12-03 | Bionomics Limited | A therapeutic protocol for treating ovarian cancer |
AU2015283811A1 (en) * | 2014-07-02 | 2017-02-09 | Bionomics Limited | Predictive biomarkers |
AU2015283795A1 (en) * | 2014-07-02 | 2017-02-09 | Bionomics Limited | Predicting response to cancer therapy |
CN104860908B (zh) * | 2015-04-28 | 2017-03-22 | 广东颐正达医药科技有限公司 | 一种合成bnc105的方法 |
NZ738406A (en) | 2015-06-11 | 2023-04-28 | Bionomics Ltd | Pharmaceutical combination of a tubulin polymerization inhibitor with an inhibitor of pd-l1, pd-1, or ctla-4 and uses and compositions thereof |
AU2016366680B2 (en) | 2015-12-09 | 2021-06-24 | The Board Of Trustees Of The University Of Illinois | Benzothiophene-based selective estrogen receptor downregulators |
EP3454856A4 (en) | 2016-05-10 | 2019-12-25 | C4 Therapeutics, Inc. | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
EP3858835A1 (en) | 2016-07-01 | 2021-08-04 | G1 Therapeutics, Inc. | Pyrimidine-based antiproliferative agents |
CN107586284B (zh) * | 2016-07-06 | 2021-03-26 | 中国药科大学 | 一种2-芳基苯并呋喃类衍生物在制备痛风药物中的用途 |
WO2018049474A1 (en) | 2016-09-16 | 2018-03-22 | Bionomics Limited | Antibody and checkpoint inhibitor combination therapy |
WO2018081168A2 (en) | 2016-10-24 | 2018-05-03 | The Board Of Trustees Of The University Of Illinois | Benzothiophene-based selective mixed estrogen receptor downregulators |
CN110177554B (zh) | 2017-01-06 | 2023-06-02 | G1治疗公司 | 用于治疗癌症的组合疗法 |
US10208011B2 (en) | 2017-02-10 | 2019-02-19 | G1 Therapeutics, Inc. | Benzothiophene estrogen receptor modulators |
CA3067873A1 (en) | 2017-06-29 | 2019-01-03 | G1 Therapeutics, Inc. | Morphic forms of g1t38 and methods of manufacture thereof |
EP3897631A4 (en) | 2018-12-20 | 2022-11-23 | C4 Therapeutics, Inc. | TARGETED PROTEIN DEGRADATION |
JP2021120367A (ja) | 2020-01-30 | 2021-08-19 | エイムドバイオ株式会社 | ベンゾセレノフェン系化合物、これを含む薬学的組成物及び抗体−薬物複合体 |
KR20240058859A (ko) | 2021-08-12 | 2024-05-03 | 쿨레온 엘엘씨 | 환각성 및 비환각성 세로토닌 수용체 작용제 및 이의 제조 및 사용 방법 |
WO2024030968A1 (en) | 2022-08-03 | 2024-02-08 | Brystol-Myers Squibb Company | Compounds for modulating ret protein |
WO2024097980A1 (en) | 2022-11-04 | 2024-05-10 | Bristol-Myers Squibb Company | Ret-ldd protein inhibitors |
WO2024097989A1 (en) | 2022-11-04 | 2024-05-10 | Bristol-Myers Squibb Company | Ret-ldd protein degraders |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE195530T1 (de) | 1992-05-20 | 2000-09-15 | Merck & Co Inc | 17-ether und thioether von 4-aza-steroiden |
CA2135173A1 (en) | 1992-05-20 | 1993-11-25 | Bruce E. Witzel | Ester derivatives of 4-aza-steroids |
EP0915090A1 (en) | 1992-09-10 | 1999-05-12 | Eli Lilly And Company | Compounds useful as hypoglycemic agents and for treating Alzheimer's disease |
ATE201398T1 (de) * | 1993-11-17 | 2001-06-15 | Kyowa Hakko Kogyo Kk | Propenon-derivate |
US5728724A (en) * | 1995-08-17 | 1998-03-17 | Eli Lilly And Company | Benzothiophene compounds |
US5886025A (en) | 1997-03-06 | 1999-03-23 | Baylor University | Anti-mitotic agents which inhibit tubulin polymerization |
CA2260499A1 (en) | 1998-01-29 | 1999-07-29 | Sumitomo Pharmaceuticals Company Limited | Pharmaceutical compositions for the treatment of ischemic brain damage |
EP1058549A4 (en) | 1998-12-23 | 2003-11-12 | Bristol Myers Squibb Pharma Co | FACTOR Xa OR THROMBIN INHIBITORS |
CA2358925C (en) * | 1999-02-18 | 2010-04-20 | Oxigene, Inc. | Compositions and methods for use in targeting vascular destruction |
JP4187441B2 (ja) | 1999-09-17 | 2008-11-26 | ベイラー・ユニバーシテイ | インドール含有およびコンブレタスタチン関連の抗有糸分裂および抗チューブリン重合薬剤 |
WO2004099139A1 (en) * | 2000-09-15 | 2004-11-18 | Baylor University | Indole-containing compounds with anti-tubulin and vascular targeting activity |
MXPA02005101A (es) | 1999-10-18 | 2003-09-25 | Alexipharma Inc | Derivados de indol canabimimeticos. |
CA2397575A1 (en) | 2000-01-13 | 2001-07-19 | Tularik Inc. | Antibacterial agents |
ATE368046T1 (de) * | 2000-03-10 | 2007-08-15 | Univ Baylor | Tubulin bindende liganden |
US7091240B2 (en) * | 2000-03-10 | 2006-08-15 | Oxigene, Inc. | Tubulin binding ligands and corresponding prodrug constructs |
DE10017947A1 (de) | 2000-04-11 | 2001-10-25 | Merck Patent Gmbh | Verfahren zur Herstellung benzo-annelierter Heterocyclen |
WO2002000651A2 (en) | 2000-06-27 | 2002-01-03 | Bristol-Myers Squibb Pharma Company | Factor xa inhibitors |
FR2813308B1 (fr) | 2000-08-23 | 2005-07-01 | Sanofi Synthelabo | Aminoalkoxybenzoyl-benzofurannes ou benzothiophenes, leur procede de preparation ainsi que les compositions les contenant |
AU2002224890B2 (en) | 2000-12-05 | 2007-03-22 | F. Hoffmann-La Roche Ag | Benzofuran and benzothiophene derivatives as selective COX-2 inhibitors |
AUPR283801A0 (en) * | 2001-02-01 | 2001-03-01 | Australian National University, The | Chemical compounds and methods |
GB0106586D0 (en) | 2001-03-16 | 2001-05-09 | Smithkline Beecham Plc | Novel compounds |
EP1411052B1 (en) | 2001-07-05 | 2011-10-05 | Takeda Pharmaceutical Company Limited | Benzo-fused 5-membered hetrocycle compounds,process for preparation of the same, and use thereof |
US7528165B2 (en) * | 2001-12-13 | 2009-05-05 | National Health Research Institutes | Indole compounds |
TWI317634B (en) * | 2001-12-13 | 2009-12-01 | Nat Health Research Institutes | Aroyl indoles compounds |
EP1400244A1 (en) | 2002-09-17 | 2004-03-24 | Warner-Lambert Company LLC | New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors |
JP2006525364A (ja) | 2003-04-30 | 2006-11-09 | ジ インスチチュート フォー ファーマシューティカル ディスカバリー、エルエルシー | 置換アミノカルボン酸 |
US7456214B2 (en) | 2004-05-03 | 2008-11-25 | Baylor University | Chromene-containing compounds with anti-tubulin and vascular targeting activity |
US20050245489A1 (en) * | 2004-05-03 | 2005-11-03 | Pinney Kevin G | Chromene-containing compounds with anti-tubulin and vascular targeting activity |
US7456289B2 (en) * | 2004-12-31 | 2008-11-25 | National Health Research Institutes | Anti-tumor compounds |
CA2597447C (en) | 2005-02-14 | 2014-03-25 | Bionomics Limited | Novel tubulin polymerisation inhibitors |
WO2007087684A1 (en) | 2006-02-03 | 2007-08-09 | Bionomics Limited | Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors |
-
2007
- 2007-02-02 WO PCT/AU2007/000101 patent/WO2007087684A1/en active Application Filing
- 2007-02-02 JP JP2008552645A patent/JP5315060B2/ja active Active
- 2007-02-02 AU AU2007211840A patent/AU2007211840B2/en active Active
- 2007-02-02 PT PT07701434T patent/PT1984333E/pt unknown
- 2007-02-02 US US12/162,917 patent/US8198466B2/en active Active
- 2007-02-02 DK DK07701434.8T patent/DK1984333T3/da active
- 2007-02-02 CA CA2640678A patent/CA2640678C/en active Active
- 2007-02-02 EP EP07701434A patent/EP1984333B1/en active Active
- 2007-02-02 ES ES07701434T patent/ES2386299T3/es active Active
- 2007-02-02 EP EP12153534A patent/EP2460793A1/en not_active Withdrawn
- 2007-02-02 NZ NZ570014A patent/NZ570014A/en unknown
- 2007-02-02 AT AT07701434T patent/ATE555091T1/de active
-
2009
- 2009-04-23 HK HK09103762.1A patent/HK1124329A1/xx not_active IP Right Cessation
-
2012
- 2012-05-01 US US13/461,213 patent/US8716335B2/en active Active
- 2012-10-22 US US13/657,160 patent/US8680135B2/en active Active
-
2014
- 2014-02-19 US US14/183,908 patent/US9346842B2/en active Active
-
2016
- 2016-04-28 US US15/141,170 patent/US10213409B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP1984333B1 (en) | 2012-04-25 |
EP1984333A1 (en) | 2008-10-29 |
US10213409B2 (en) | 2019-02-26 |
PT1984333E (pt) | 2012-07-16 |
ATE555091T1 (de) | 2012-05-15 |
US8716335B2 (en) | 2014-05-06 |
US20120214770A1 (en) | 2012-08-23 |
AU2007211840B2 (en) | 2012-03-01 |
AU2007211840A1 (en) | 2007-08-09 |
US8198466B2 (en) | 2012-06-12 |
US8680135B2 (en) | 2014-03-25 |
US9346842B2 (en) | 2016-05-24 |
EP2460793A1 (en) | 2012-06-06 |
US20140171642A1 (en) | 2014-06-19 |
US20130053351A1 (en) | 2013-02-28 |
EP1984333A4 (en) | 2010-05-19 |
ES2386299T3 (es) | 2012-08-16 |
CA2640678C (en) | 2015-03-31 |
US20100004208A1 (en) | 2010-01-07 |
CA2640678A1 (en) | 2007-08-09 |
JP2009531281A (ja) | 2009-09-03 |
DK1984333T3 (da) | 2012-07-23 |
NZ570014A (en) | 2011-04-29 |
WO2007087684A1 (en) | 2007-08-09 |
US20170020840A1 (en) | 2017-01-26 |
JP5315060B2 (ja) | 2013-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1124329A1 (en) | Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors | |
HK1137737A1 (en) | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs 4-(())- | |
ATE520656T1 (de) | Verfahren zur herstellung von 2-oxo-1- pyrrolidinderivaten | |
DE602004017736D1 (de) | Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust | |
WO2005044976A3 (en) | Oligomeric compounds for use in gene modulation | |
WO2003053997A3 (en) | Methods of increasing endogenous erythropoietin (epo) | |
WO2004098494A3 (en) | Compounds, compositions, and methods | |
WO2006034093A3 (en) | 3- (2-acylamino-1-hydroxyethyl)- morpholine derivatives and their use as bace inhibitors | |
WO2007011760A3 (en) | Inhibitors of mitotic kinesin | |
DE602005020666D1 (en) | Mif-hemmer | |
WO2007011759A3 (en) | Inhibitors of mitotic kinesin | |
DE602006017837D1 (de) | Azabicycloä3.1.0ühexan-derivate als modulatoren des dopamin-d3-rezeptors | |
DE602005005298D1 (de) | 1-benzyl-5-piperazin-1-yl-3,4 dihydro-1h-chinazolin-2-on-derivate und die jeweiligen 1h-benzo(1,2,6)thiadiazin-2,2-dioxid und 1,4-dihydro-benzo(d)(1,3)oxazin-2-on-derivate als modulatoren des 5-hydroxytryptamin-rezeptors (5-ht) zur behandlung von erk | |
WO2006081516A3 (en) | USE OF BAFF TO TREAT Th2-MEDIATED CONDITIONS | |
ATE410166T1 (de) | 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin- derivate zur behandlung von unfruchtbarkeit | |
WO2004110990A3 (en) | Imidazothiazoles and imidazoxazole derivatives as inhibitors of p38 | |
ECSP056057A (es) | Compuestos de benzo[1,2,5]tiadiazole | |
WO2005014536A3 (en) | Podophyllotoxin derivatives | |
PL1680430T3 (pl) | Sposoby wytwarzania postaci i (s)-(+)-wodorosiarczanu klopidogrelu | |
TW200503619A (en) | Use of isoindolinone derivatives as insecticides | |
IL138688A0 (en) | Certain heteroaryl substituted thiol inhibitors of endothelin-converting enzyme | |
WO2005034879A3 (en) | Treatment of diseases involving erbb2 kinase overexpression | |
SG149041A1 (en) | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | |
MX2007016120A (es) | Induccion de vasodilatacion de vasos sanguineos perifericos. | |
WO2005024100A3 (en) | Fibrillar apparatus and methods for making it |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20170202 |